摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4,6-二甲基呋喃并[2,3-D]嘧啶-2-胺 | 22727-43-1

中文名称
4,6-二甲基呋喃并[2,3-D]嘧啶-2-胺
中文别名
——
英文名称
4,6-Dimethylfuro[2,3-d]pyrimidin-2-amine
英文别名
——
4,6-二甲基呋喃并[2,3-D]嘧啶-2-胺化学式
CAS
22727-43-1
化学式
C8H9N3O
mdl
MFCD00461660
分子量
163.18
InChiKey
MSEVJFYMGKQFNO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    246-248 °C(Solv: hexane (110-54-3))
  • 沸点:
    353.8±34.0 °C(Predicted)
  • 密度:
    1.278±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.4
  • 重原子数:
    12
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    64.9
  • 氢给体数:
    1
  • 氢受体数:
    4

安全信息

  • 安全说明:
    S26
  • 危险类别码:
    R36

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] SUBSTITUTED 2, 4-DIAMINO-QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES<br/>[FR] DÉRIVÉS SUBSTITUÉS DE 2, 4-DIAMINO-QUINOLÉINE POUR LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES PROLIFÉRATIVES
    申请人:GENOSCIENCE PHARMA
    公开号:WO2017191599A1
    公开(公告)日:2017-11-09
    This application discloses compounds according to generic Formula (I): wherein all variables are defined as described herein which exhibit strong inhibition effects on various cancer cell lines. The compounds disclosed herein are useful for the treatment of proliferative diseases, including neoplastic diseases such as cancer and non- neoplastic disorders such as rheumatoid arthritis. Also disclosed are pharmaceutical compositions containing compounds of Formula (I) and at least one carrier, diluent or excipient and optionally one or more additional therapeutically active agents, including anticancer agents. This application also discloses methods for treating a proliferative disease, including neoplastic diseases such as cancer and non- neoplastic disorders such as rheumatoid arthritis.
    本申请披露了根据通用式(I)定义的化合物,其中所有变量如本文所述,这些化合物对各种癌细胞系表现出强烈的抑制作用。本文披露的化合物对于治疗增生性疾病非常有用,包括肿瘤性疾病如癌症和非肿瘤性疾病如类风湿性关节炎。还披露了含有通用式(I)化合物和至少一种载体、稀释剂或赋形剂以及可选的一种或多种其他治疗活性剂的药物组合物。本申请还披露了治疗增生性疾病的方法,包括肿瘤性疾病如癌症和非肿瘤性疾病如类风湿性关节炎的方法。
  • Herbicidal sulfonamides
    申请人:E. I. Du Pont de Nemours and Company
    公开号:US04487626A1
    公开(公告)日:1984-12-11
    This invention relates to a novel class of arylsulfonylureidofuro[2,3-d]pyrimidines, such as N'-[(4,6-dimethylfuro[2,3-d]pyrimidin-2-yl)aminocarbonyl]-N,N-dimethylbenz ene-1,2-sulfonamide, and their use as herbicides and plant growth regulants. These novel compounds can be prepared by reacting an appropriate furo[2,3-d]pyrimidin-2-amine with an appropriately substituted arylsulfonyl isocyanate or isothiocyanate.
    本发明涉及一种新型的芳基磺酰呋喃[2,3-d]嘧啶类化合物,例如N'-[(4,6-二甲基呋喃[2,3-d]嘧啶-2-基)基甲酰]-N,N-二甲基苯-1,2-磺酰胺,以及它们作为除草剂植物生长调节剂的用途。这些新型化合物可以通过将适当的呋喃[2,3-d]嘧啶-2-胺与适当取代的芳基磺酰异氰酸酯或异硫氰酸酯反应而制备得到。
  • Sulfonylurea N-oxides
    申请人:E.I. DU PONT DE NEMOURS AND COMPANY
    公开号:EP0057546A2
    公开(公告)日:1982-08-11
    Compounds of the formula and their agriculturally suitable salts, where A is where R, R2 and R3 are halogen, NO2 or various organic groups; R1 and R13 are H, halogen, N02 or various organic groups; W is H or CH3; and L is where X is CH3, C2H5, CH30 or C2H5O: Y and X1 are H, Cl or various organic groups; Y1 is 0 or CH2; X2 is CH3 or C2H5; Z is CH, CF or N; and Q is O bonded to a nitrogen atom of L; exhibit herbicidal and plant growth regulant effects. They may be formulated for use in conventional manner. The compounds may be made by reacting an isocyanate with an aminopyrimidine-N-oxide or aminotriazine-N-oxide Some of the novel compounds can be made by esterifying the corresponding novel carboxylic acids wherein R or R3 is C02H.
    式中的化合物 及其农业上适用的盐类,其中 A 是 其中 R、R2 和 R3 是卤素、NO2 或各种有机基团;R1 和 R13 是 H、卤素、N02 或各种有机基团;W 是 H 或 CH3;以及 L 是 其中 X 是 、C2H5、 0 或 O: Y 和 X1 是 H、Cl 或各种有机基团; Y1 是 0 或 CH2; X2 是 或 ; Z 是 CH、CF 或 N;以及 Q 是与 L 的氮原子结合的 O; 具有除草和植物生长调节作用。它们可按常规方法配制使用。这些化合物可通过异氰酸酯氨基嘧啶反应制成 与氨基嘧啶-N-氧化物或基三嗪-N-氧化物反应制得。 某些新型化合物可通过酯化相应的新型羧酸制成,其中 R 或 R3 为 C02H。
  • Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases
    申请人:GENOSCIENCE PHARMA
    公开号:US10577362B2
    公开(公告)日:2020-03-03
    This application discloses compounds according to generic Formula I: wherein all variables are defined as described herein which exhibit strong inhibition effects on various cancer cell lines. The compounds disclosed herein are useful for the treatment of proliferative diseases, including neoplastic diseases such as cancer and non-neoplastic disorders such as rheumatoid arthritis. Also disclosed are pharmaceutical compositions containing compounds of Formula I and at least one carrier, diluent or excipient and optionally one or more additional therapeutically active agents, including anticancer agents. This application also discloses methods for treating a proliferative disease, including neoplastic diseases such as cancer and non-neoplastic disorders such as rheumatoid arthritis.
    本申请公开了符合通式 I 的化合物:其中所有变量的定义如本文所述,这些化合物对各种癌细胞系具有很强的抑制作用。本文公开的化合物可用于治疗增殖性疾病,包括肿瘤性疾病(如癌症)和非肿瘤性疾病(如类风湿性关节炎)。本申请还公开了含有式 I 化合物和至少一种载体、稀释剂或赋形剂的药物组合物,以及一种或多种额外的治疗活性剂,包括抗癌剂。本申请还公开了治疗增殖性疾病的方法,包括肿瘤性疾病如癌症和非肿瘤性疾病如类风湿性关节炎。
  • GAPOYAN, A. S.;MIRZOYAN, V. S.;XACHATRYAN, V. EH.;MELIK-OGANDZHANYAN, R. +, ARM. XIM. ZH., 41,(1988) N 6, 339-346
    作者:GAPOYAN, A. S.、MIRZOYAN, V. S.、XACHATRYAN, V. EH.、MELIK-OGANDZHANYAN, R. +
    DOI:——
    日期:——
查看更多

同类化合物

呋喃并[2,3-d]嘧啶-4(1H)-酮 呋喃并[2,3-d]嘧啶-2(3H)-酮 呋喃并[2,3-d]嘧啶 6-苯基呋喃并[2,3-D]嘧啶-4-胺 6-甲基呋喃并[2,3-d]嘧啶-4-胺 6-甲基呋喃并[2,3-d]嘧啶-4(3H)-酮 6-(4-甲氧基苯基)呋喃并[2,3-d]嘧啶-4-胺 6-(4-甲氧基苯基)-5-(3-吡啶)-呋喃并[2,3-d]嘧啶-4-胺 6-(4-甲基苯基)-呋喃并[2,3-d]嘧啶-4-胺 6-(4-溴-苯基)-4-氯-呋喃并[2,3-d]嘧啶 6-(4-氯苯基)-呋喃并[2,3-d]嘧啶-4-胺 6-(3-溴-苯基)-4-氯-呋喃并[2,3-d]嘧啶 6-(3-吡啶)-呋喃并[2,3-d]嘧啶-4-胺 5-甲基呋喃并[2,3-d]嘧啶-4-胺 5-溴呋喃并[2,3-D]嘧啶-4-胺 5-氯甲基呋喃并[2,3-d]嘧啶-2,4-二胺 5,6-二甲基呋喃[2,3-d]嘧啶-4-胺 4-氯呋喃[2,3-D]嘧啶 4-氯-6-甲基-呋喃并[2,3-d]嘧啶 4-氨基呋喃并[2,3-D]嘧啶 4,6-二甲基呋喃并[2,3-d]嘧啶 4,6-二甲基呋喃并[2,3-D]嘧啶-2-胺 3-(2-脱氧-beta-D-赤式-呋喃戊糖基)-6-甲基呋喃并[2,3-d]嘧啶-2(3H)-酮 2-甲基硫代呋喃并[2,3-d]嘧啶-6-甲醇 2,4-二氯呋喃并[2,3-d]嘧啶 2,4-二氯-5-甲基呋喃并[2,3-d]嘧啶 2-Methyl-4-diacetylamino-5,6-bis-(2-furyl)furo<2,3-d>pyrimidine 3-[1-methyl-6-(5-nitro-furan-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino]-propan-1-ol 1-Methyl-4-(1-methyl-2-methoxy-ethyl-amino)-6-(5-nitro-2-furyl)-1H-pyrazolo<3.4-d>pyrimidin 2-Ethyl-4-amino-5,6-bis-(2-furyl)furo<2,3-d>pyrimidine 3-[3’,5’-di-O-(tert-butyldimethylsilyl)-2’-deoxy-β-D-ribofuranosyl]-6-(p-pentylphenyl)-2,3-dihydrofuro[2,3-d]pyrimidin-2-one 2,6-dimethyl-3H-furo[2,3-d]pyrimidine-4-thione 4-hydrazino-6-methyl-2-phenyl-furo[2,3-d]pyrimidine 3-[3'-O-(tert-butyldimethylsilyl)-2'-deoxy-β-D-ribofuranosyl]-6-(p-pentylphenyl)-2,3-dihydrofuro[2,3-d]pyrimidin-2-one 4-Ethylamino-6-methylfuro<4,5-b>pyrimidin 6-[Diethoxy(oxido)phosphaniumyl]furo[2,3-d]pyrimidine t counted 4-methoxy-2,6-dimethyl-furo[2,3-d]pyrimidine 3-(2-deoxy-β-D-erythro-pentofuranosyl)-6-ethynyl-furo[2,3-d]pyrimidin-2(3H)-one ethyl (4-oxo-5-phenyl-3,4-dihydrofuro[2,3-d]pyrimidin-2-yl)acetate 2,2'-[3-methyl-6-(5-nitro-furan-2-yl)-isoxazolo[5,4-d]pyrimidin-4-ylazanediyl]-bis-ethanol 5-[(R/S)-2-(2'-methoxyphenyl)pentyl]furo[2,3-d]pyrimidine-2,4-diamine 5-acetyl-6-(benzyloxy)-2,4-dimethylfuro<2,3-b>pyridine 5-[(R/S)-2-(2'-methoxyphenyl)-3-methylbutyl]furo[2,3-d]-pyrimidine-2,4-diamine furan-2-carboxylic acid N'-{2-amino-7-[2-(t-butyldimethylsilanyloxy)ethyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-hydrazide 2-(5-phenylfuro[2,3-d]pyrimidin-4-ylamino)ethanol 5-[(R/S)-2-(2'-methoxyphenyl)-4-methylpentyl]furo[2,3-d]pyrimidine-2,4-diamine 5-[(R/S)-2-(2'-methoxyphenyl)hexyl]furo[2,3-d]pyrimidine-2,4-diamine tert-butyl 3-<6'-(benzyloxy)-2',4'-dimethylfuro<2,3-b>-pyrid-5'-yl>-3-hydroxybutanoate 6-(benzyloxy)-2,4-dimethylfuro<2,3-b>pyridine-5-carboxaldehyde